Neurocrine Biosciences director George Morrow filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 14,700 shares of common stock acquired through stock option exercises, with an aggregate market value of $2,147,670.00.
Key Highlights
- Proposed seller: George Morrow, a director of Neurocrine Biosciences, Inc.
- Shares proposed for sale: 14,700 shares of common stock, with an aggregate market value of $2,147,670.00.
- Acquisition method: Shares are to be received through the exercise of stock options, with the date of acquisition and payment listed as November 2, 2026.
- Approximate date of sale: November 2, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
- Prior sales in past 3 months: 300 shares of common stock sold on October 30, 2026, generating gross proceeds of $44,700.00, under a Rule 10b5-1 plan.
- Trading plan: The Rule 10b5-1 plan was adopted on May 26, 2026, according to the filing.
- Shares outstanding: 101,649,181 shares of common stock outstanding, as stated in the filing.
Morrow's Proposed Stock Option Sale at Neurocrine Biosciences
According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, George Morrow, identified as a director of Neurocrine Biosciences, Inc. (NASDAQ:NBIX), proposed to sell 14,700 shares of the company's common stock. The filing lists the approximate date of sale as November 2, 2026, with the transaction to be conducted through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
The filing discloses that the shares to be sold were and will be acquired through the exercise of stock options granted by the issuer. The date of acquisition and payment are listed as November 2, 2026, with cash as the nature of payment. The filing's remarks section states: "The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale."
The filing also discloses that, within the past three months, Morrow sold 300 shares of common stock on October 30, 2026, generating gross proceeds of $44,700.00. Those prior sales are listed as 10b5-1 plan sales. The current proposed sale is also conducted under a Rule 10b5-1 plan adopted on May 26, 2026, as indicated in the filing. The total shares of common stock outstanding are listed as 101,649,181.
What Was Disclosed
Neurocrine Biosciences director George Morrow filed a Form 144 proposing to sell 14,700 shares of common stock valued at $2,147,670.00, acquired via stock option exercises, under a Rule 10b5-1 plan adopted May 26, 2026.



Please wait processing your request...